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The	 recent	 paradigm	 shift	 in	 infectious	 disease	diagnosis	
from	culture-based	 to	molecular-based	approaches	 is	 ex-
emplified	 in	 the	findings	of	a	national	study	assessing	the	
detection of verotoxigenic Escherichia coli infections in Ire-
land.	The	methodologic	changes	have	been	accompanied	
by	a	dramatic	increase	in	detections	of	non-O157	verotoxi-
genic E. coli serotypes.
Verotoxigenic Escherichia coli (VTEC) can cause severe disease in humans, with signs and symptoms includ-
ing diarrhea, hemorrhagic colitis, and hemolytic uremic syn-
drome (1). The primary reservoir of VTEC is ruminants, and 
sporadic outbreaks are commonly associated with animal 
contact, exposure to animal feces, food and water contami-
nation, and person-to-person transmission (2).
In Ireland, a country with a population of ≈4.6 million, 
all VTEC infections have been notifiable to the Medical Of-
ficer of Health since 2004. Initially, these infections were 
included under specified infections caused by enterohemor-
rhagic E. coli (EHEC), comprising any strains of serogroups 
O157, O26, O103, O111, and O145 (3); since an amendment 
of September 2011, these infections have been specified as 
VTEC infections (4). Data on VTEC infections in Europe 
have been provided since 2008 from the member states to the 
European Centre for Disease Prevention and Control. These 
data indicate that Ireland had the highest annual incidence 
of VTEC infection during 2009–2014, with the exception of 
2011, when a large outbreak of E. coli O104:H4 infections 
occurred in Germany (5). The Health Protection and Surveil-
lance Centre releases annual reports on the number of VTEC 
infection cases in Ireland, which document an increase in the 
number of VTEC infections in Ireland during 2010–2014 
(Figure). This trend is thought to be largely attributable to 
an increase in non-O157 VTEC infections. A low infectious 
dose of ≈10 microorganisms has been described as sufficient 
to cause disease that can lead to hemolytic uremic syndrome 
(6). Real-time PCR (rPCR) has been demonstrated as a more 
rapid and sensitive method of VTEC detection, compared 
with enzyme immunoassay and culture (7).
We conducted a survey of clinical microbiology labo-
ratories in Ireland during 2014 to assess laboratory prac-
tices for the detection and confirmation of VTEC infection. 
The survey included 45 questions, arranged in 4 categories: 
laboratory details (e.g., contact details, address, and public/
private status); sample type, selection, and requirements 
for VTEC testing; current methods (i.e., utilization and 
description of enrichment, culture, biochemical charac-
terization, antimicrobial susceptibility testing, serotyping, 
molecular testing, and verotoxin detection methods), past 
changes to methods, and intended future changes to meth-
ods for VTEC analyses; and referral and reporting proce-
dures. Ireland is home to 25 clinical microbiology labora-
tories, all of which were represented in the survey findings 
presented here. Laboratories included the VTEC National 
Reference Laboratory in Cherry Orchard Hospital, Dublin, 
which provides the referral service for this pathogen to all 
clinical laboratories in Ireland, whether public or private. 
Laboratories were categorized into 3 groups based on their 
testing strategy: culture-based detection, PCR-based detec-
tion, or both. An analysis of the introduction of molecular-
based detection of VTEC infection (i.e., rPCR of verotoxin 
genes vt1 and vt2) in clinical laboratories in Ireland indi-
cated a timeline for the implementation of these methods 
from 2010 to 2014. Before 2012, the reference laboratory 
was the sole laboratory implementing PCR-based detec-
tion of VTEC. In 2012, a regional clinical laboratory intro-
duced an automated molecular platform for the detection 
of VTEC and other gastrointestinal pathogens. Four more 
laboratories introduced this molecular platform in 2013, 
with another 2 converting in 2014. Five clinical laborato-
ries expressed an intention to introduce PCR-based detec-
tion of VTEC starting in 2015.
These data represent a shifting trend from the conven-
tional culture-based detection of fecal coliforms (with con-
firmatory testing as VTEC), to a direct molecular approach 
in which stool specimens are tested initially for the pres-
ence of the verotoxin genes. This move toward molecular 
detection of VTEC infection is consistent with the increased 
number of non-O157 VTEC cases reported in Ireland in 
recent years (Figure). Similar results were reported in a 
study of the same nature conducted in Washington, USA 
(8). Along with the increased number of clinical laborato-
ries participating in molecular detection of VTEC, a con-
comitant shift has occurred in the culture-based detection 
of VTEC. The introduction of an agar for the detection of 
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Shiga-toxin–producing E. coli (CHROMagar STEC; Mast 
Diagnostika, Reinfeld, Germany) to laboratories, which is 
selective for the top 6 non-O157 serogroups (O26, O45, 
O103, O111, O121, and O145), supports the recently held 
view that a range of VTEC serogroups are now considered 
a major cause of human VTEC infection (5,9).
With the exception of the reference laboratory, molec-
ular VTEC detection in clinical laboratories in Ireland use 
a commercial rPCR-based platform. This method, which 
selects for verotoxin genes, accelerates more sensitive de-
tection compared with traditional culture-based methods.
Our own recent observations in Ireland (10,11) may 
very well represent the start of a global trend toward molecu-
lar detection of verotoxin genes from clinical and other sam-
ples, to replace culture-based methods, as a first step in the 
detection of VTEC (12). Our findings suggest that increases 
in notifications of VTEC infections, and particularly those 
caused by non-O157 serotypes, be interpreted in light of this 
paradigm shift in infectious disease diagnostic methods.
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Figure.	Number	of	reported	cases	of	O157	and	non-O157	VTEC	
infection	and	number	of	laboratories	performing	PCR-based	
detection of stx	gene,	by	year,	Ireland,	2010–2014.	stx,	Shiga	
toxin;	VTEC,	verotoxigenic	Escherichia coli.
